Survival analysis performed with UALCAN showed that a high NFE2L2 expression in pancreatic carcinoma patients has a correlation with poor prognosis (p-value: 0.023), while in colorectal carcinoma and glioblastoma patients, no significant changes were observed in survival analysis (data not shown). This evidence concerns the gene NFE2L2 and glioblastoma.